3-amino-4-cyclobutyl-2-hydroxybutanamide

We are 3-amino-4-cyclobutyl-2-hydroxybutanamide CAS:746598-16-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-amino-4-cyclobutyl-2-hydroxybutanamide
CAS.NO:746598-16-3
Synonyms:3-amino-4-cyclobutyl-2-hydroxybutanamide
3-amino-3-cyclobutylmethyl-2-hydroxypropionamide
 
Physical and Chemical Properties:
Molecular Formula C8H16N2O2
Molecular Weight 172.22500
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Boceprevir(CAS:394730-60-0).

3-amino-4-cyclobutyl-2-hydroxybutanamide


Related News: “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.5-bromo-2-cloro-3-metilpiridina CAS:29241-60-9 “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”sodium,4-chloro-1-hydroxybutane-1-sulfonate The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.105-76-0 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.

Related Products
Product Name
D-Phenylalanine View Details
3′-Deoxy-3′-fluoro Thymidine View Details
Trimethoxy(1H,1H,2H,2H-perfluorohexyl)silane View Details
DL-Arginine Monohydrochloride Monohydrate manufacturer 2,4-Dichloropyrimidine manufacturer 2,4-ditert-butyl-6-[[[3-[(3,5-ditert-butyl-6-oxocyclohexa-2,4-dien-1-ylidene)methylamino]-2,3-dimethylbutan-2-yl]amino]methylidene]cyclohexa-2,4-dien-1-one Cas:351498-10-7 manufacturer 4-Chlorophenyl Cyclopropyl Ketone manufacturer gamma-LINOLENIC ACID ETHYL ESTER manufacturer